Sanjay Popat, Thoracic Oncologist at The Royal Marsden NHS Foundation Trust, shared a post on X:
“Becotarug (JMT101) IgG EGFR AB and osimertinib cohort expansion in treatment-naive EGFR mutation 19/21. N=33 ORR 78.8% PFS 20.8mo, AEs per EGFR type. Phase 2/3 trials planned. Hmm…”
More posts featuring Sanjay Popat.
